In TNBS-induced colitis mice, rectally administered Fluc mRNA MP2 LNPs gave approximately 15-fold higher colonic luminescence than the study's SM102 formulation at 6 hours (0.5 mg/kg mRNA; n = 3 mice per group; Fig. 1g).
| CAS No. | Not reported |
| Chemical Name | MP2 |
| SMILES | CCCCCCCCOCOCCCCN(CCCCCCOC(=O)CCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C)CCCN(CCCCOCOCCCCCCCC)CCCCOCOCCCCCCCC |
| Formula | C74H132N2O14 |
| M.Wt | 1273.87 |
| Purity | >95% by ELSD-HPLC |
| Storage | Request batch-specific handling guidance |
| Product classification | Ionizable lipids for colonic RNA delivery; Cationic/Ionizable Lipids |
| Publication | Cao D, et al. Anti-inflammation lipid nanoparticles enable localized mRNA therapy for inflammatory bowel disease. Nature Communications (2026). doi:10.1038/s41467-026-78302-5 |
Literature-reported MP2 LNP composition
| Component | Reported ratio | Role |
|---|---|---|
| MP2 | 20 | Ionizable lipid |
| DOPE | 30 | Helper phospholipid |
| Cholesterol | 40 | Sterol |
| DMG-PEG2k | 0.75 | PEG lipid |
| Sum of printed values | 90.75 | Confirm with the authors before reproducing |
Reported study results
MP2 was among the five three-tail steroid-derived formulations with more than 30-fold higher Fluc mRNA expression than the study's SM102 formulation in Caco-2 cells (0.5 µg/mL mRNA; 18 hours; n = 4 wells per group; Fig. 1f).
IL-35 mRNA-loaded MP2 LNPs improved clinical and colonic inflammation measures in TNBS acute and IL-10 knockout chronic mouse colitis models. The IL-10 knockout study reported disease activity index 0.38 for MP2-IL-35 versus 3.75 for SM102-IL-35 at week 18 (1 mg/kg mRNA rectally each week; Fig. 4).
MP2 LNPs delivered GFP mRNA to immune, epithelial and endothelial cells in human colonic biopsies. IL-35 mRNA-loaded MP2 LNPs were also studied in IBD patient biopsies for cytokine and T-cell readouts (Fig. 5).
Reference: Cao D, Tian M, Yu C, et al. Nature Communications (2026), doi:10.1038/s41467-026-78302-5. Structure and analytical record: Supplementary Fig. 1 and MP2 NMR/MALDI-MS; LNP composition: Methods. The reported molar ratio totals 90.75 and has not been normalized here. Published performance reflects the stated formulation, cargo, dose and model.